MX2015016536A - Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif. - Google Patents

Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.

Info

Publication number
MX2015016536A
MX2015016536A MX2015016536A MX2015016536A MX2015016536A MX 2015016536 A MX2015016536 A MX 2015016536A MX 2015016536 A MX2015016536 A MX 2015016536A MX 2015016536 A MX2015016536 A MX 2015016536A MX 2015016536 A MX2015016536 A MX 2015016536A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
hydroxylase inhibitor
hif hydroxylase
hif
inhibitor
Prior art date
Application number
MX2015016536A
Other languages
English (en)
Inventor
Witschi Claudia
CONCA David
Allen Flippin Lee
David LEIGH Scott
Robert Wright Lee
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015016536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX2015016536A publication Critical patent/MX2015016536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a formulaciones farmacéuticas de ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)-ami no]-acético y métodos de uso de las mismos.
MX2015016536A 2013-06-06 2014-06-05 Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif. MX2015016536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
MX2015016536A true MX2015016536A (es) 2016-08-11

Family

ID=51063834

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015016536A MX2015016536A (es) 2013-06-06 2014-06-05 Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.
MX2020003096A MX2020003096A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
MX2022011225A MX2022011225A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020003096A MX2020003096A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
MX2022011225A MX2022011225A (es) 2013-06-06 2015-12-01 Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.

Country Status (24)

Country Link
US (3) US20160120859A1 (es)
EP (2) EP3003284B1 (es)
JP (4) JP6604941B2 (es)
KR (3) KR20220164069A (es)
CN (5) CN111728951A (es)
AU (1) AU2014274890B2 (es)
CA (1) CA2914049C (es)
CY (1) CY1122951T1 (es)
DK (1) DK3003284T3 (es)
ES (1) ES2786924T3 (es)
HK (1) HK1222550A1 (es)
HR (1) HRP20200615T1 (es)
HU (1) HUE049623T2 (es)
IL (3) IL296484A (es)
LT (1) LT3003284T (es)
ME (1) ME03777B (es)
MX (3) MX2015016536A (es)
PL (1) PL3003284T3 (es)
PT (1) PT3003284T (es)
RS (1) RS60464B1 (es)
SG (1) SG11201509764RA (es)
SI (1) SI3003284T1 (es)
WO (1) WO2014197660A1 (es)
ZA (1) ZA201508712B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977015B (zh) 2003-06-06 2015-05-06 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
PT2872488T (pt) 2012-07-16 2018-11-22 Fibrogen Inc Formas cristalinas do ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)amino]acético inibidor da prolil-hidroxilase
PT3003284T (pt) 2013-06-06 2020-08-10 Fibrogen Inc Formulações farmacêuticas de um inibidor da hidroxilase do fih
PL3277270T3 (pl) * 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CN111065625A (zh) * 2017-09-04 2020-04-24 桑多斯股份公司 口服可利用的hif脯氨酰羟化酶抑制剂的共晶
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
CN115279342A (zh) * 2020-03-17 2022-11-01 兹杜斯生命科学有限公司 包含hif脯氨酰羟化酶抑制剂的制剂
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) * 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20030176317A1 (en) 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
MEP10808A (en) 2002-12-16 2010-06-10 Kissei Pharmaceutical Solid drug for oral use
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN102977015B (zh) 2003-06-06 2015-05-06 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
CA2559630C (en) 2004-03-16 2012-04-17 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
BRPI0611670A2 (pt) 2005-06-15 2016-11-16 Fibrogen Inc método para o tratamento ou prevenção de câncer em um indivíduo
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
DK1944029T3 (da) 2005-10-31 2012-01-23 Kowa Co Farmaceutisk præparat med fremragende fotostabilitet
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
MX2008009581A (es) 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
PT2209501E (pt) 2007-10-12 2012-02-03 Astrazeneca Ab Composição de zibotentan contendo manitol e celulose microcristalina
EP2222305A1 (en) 2007-11-02 2010-09-01 Fibrogen, Inc. Methods for reducing blood pressure
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20110039885A1 (en) 2007-12-06 2011-02-17 Fibrogen, Inc. Methods for increasing endothelial progenitor cells
EP2231156A1 (en) 2007-12-07 2010-09-29 Fibrogen, Inc. Methods for increasing white blood cells
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
EP2341904A1 (en) 2008-08-26 2011-07-13 Fibrogen, Inc. Methods for treatment of multiple sclerosis
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
KR20110117133A (ko) 2009-01-29 2011-10-26 다이닛본 스미토모 세이야꾸 가부시끼가이샤 내핵을 갖는 구강 내 붕괴 정
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US20140057941A1 (en) 2011-01-13 2014-02-27 Kin-Hung (Peony) Yu Methods For Increasing Mean Corpuscular Volume
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
AU2013229922B2 (en) 2012-03-09 2017-09-28 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
PT2872488T (pt) 2012-07-16 2018-11-22 Fibrogen Inc Formas cristalinas do ácido [(4-hidroxi-1-metil-7-fenoxi-isoquinolina-3-carbonil)amino]acético inibidor da prolil-hidroxilase
KR102233081B1 (ko) 2013-01-24 2021-03-29 피브로겐, 인크. 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
PT3003284T (pt) 2013-06-06 2020-08-10 Fibrogen Inc Formulações farmacêuticas de um inibidor da hidroxilase do fih

Also Published As

Publication number Publication date
CA2914049A1 (en) 2014-12-11
SG11201509764RA (en) 2015-12-30
KR20220164069A (ko) 2022-12-12
KR20160018514A (ko) 2016-02-17
JP2023068197A (ja) 2023-05-16
IL298998B1 (en) 2024-03-01
NZ714554A (en) 2021-06-25
CN110448537A (zh) 2019-11-15
SI3003284T1 (sl) 2020-08-31
EP3003284B1 (en) 2020-02-12
PT3003284T (pt) 2020-08-10
CA2914049C (en) 2021-10-12
ES2786924T3 (es) 2020-10-14
CY1122951T1 (el) 2021-10-29
HK1222550A1 (zh) 2017-07-07
IL242759B2 (en) 2023-05-01
AU2014274890A1 (en) 2015-12-17
NZ754196A (en) 2021-06-25
US10765672B2 (en) 2020-09-08
JP6861758B2 (ja) 2021-04-21
CN111728950A (zh) 2020-10-02
EP3708154A1 (en) 2020-09-16
IL242759B1 (en) 2023-01-01
CN111728952A (zh) 2020-10-02
KR102291860B1 (ko) 2021-08-20
JP2016523846A (ja) 2016-08-12
DK3003284T3 (da) 2020-03-30
IL242759A (es) 2015-12-31
RU2681304C2 (ru) 2019-03-06
RS60464B1 (sr) 2020-07-31
IL298998A (en) 2023-02-01
JP2019137703A (ja) 2019-08-22
MX2020003096A (es) 2020-08-17
WO2014197660A1 (en) 2014-12-11
US20190008846A1 (en) 2019-01-10
BR112015029693A8 (pt) 2019-12-24
HUE049623T2 (hu) 2020-09-28
AU2014274890B2 (en) 2019-10-03
PL3003284T3 (pl) 2020-08-10
BR112015029693A2 (pt) 2017-07-25
RU2015151056A3 (es) 2018-05-03
US20220054474A1 (en) 2022-02-24
IL296484A (en) 2022-11-01
KR20210104173A (ko) 2021-08-24
HRP20200615T1 (hr) 2020-07-10
JP2021100971A (ja) 2021-07-08
ZA201508712B (en) 2020-07-29
US20160120859A1 (en) 2016-05-05
CN111728951A (zh) 2020-10-02
JP6604941B2 (ja) 2019-11-13
LT3003284T (lt) 2020-04-27
RU2015151056A (ru) 2017-07-14
EP3003284A1 (en) 2016-04-13
ME03777B (me) 2021-04-20
MX2022011225A (es) 2022-10-07
CN105377242A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201691582A1 (ru) Новые фармацевтические препараты
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
IN2012DE00912A (es)
GT201300003A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion , y las composiciones farmacèuticas que la contienen
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
IN2013MU01111A (es)
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
EP2948143A4 (en) Use of phenoxypropylamine compounds to treat depression
IN2015DN03114A (es)
PT3075738T (pt) Derivado de ácido glicirretínico e utilização do mesmo
IN2013CH03945A (es)
IN2013MU01318A (es)
BR112015029622A2 (pt) pigmentos ácidos, processos para sua produção e seu uso
MX2016007130A (es) Nuevo procedimiento de sintesis del 7-metoxi-naftaleno-1-carbaldeh ido y aplicacion en la sintesis de la agomelatina.
IN2013MU02279A (es)
UY33803A (es) Formas de dosificación de liberación modificada novedosas de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa
RU2012144184A (ru) Применение препаратов гуминовых кислот в качестве ингибиторов липазы

Legal Events

Date Code Title Description
FG Grant or registration